Publication:
Induction of long-lasting regulatory B lymphocytes by modified immune cells in kidney transplant recipients

dc.contributor.coauthorMorath, Christian
dc.contributor.coauthorSchaier, Matthias
dc.contributor.coauthorIbrahim, Eman
dc.contributor.coauthorWang, Lei
dc.contributor.coauthorKleist, Christian
dc.contributor.coauthorOpelz, Gerhard
dc.contributor.coauthorPonath, Gerald
dc.contributor.coauthorAly, Mostafa
dc.contributor.coauthorAlvarez, Cristiam M.
dc.contributor.coauthorKälble, Florian
dc.contributor.coauthorSpeer, Claudius
dc.contributor.coauthorBenning, Louise
dc.contributor.coauthorNusshag, Christian
dc.contributor.coauthorPego Da Silva, Luiza
dc.contributor.coauthorSommerer, Claudia
dc.contributor.coauthorHückelhoven-Krauss, Angela
dc.contributor.coauthorCzock, David
dc.contributor.coauthorMehrabi, Arianeb
dc.contributor.coauthorSchwab, Constantin
dc.contributor.coauthorWaldherr, Rüdiger
dc.contributor.coauthorSchnitzler, Paul
dc.contributor.coauthorMerle, Uta
dc.contributor.coauthorTran, Thuong Hien
dc.contributor.coauthorScherer, Sabine
dc.contributor.coauthorBöhmig, Georg A.
dc.contributor.coauthorMüller-Tidow, Carsten
dc.contributor.coauthorReiser, Jochen
dc.contributor.coauthorZeier, Martin
dc.contributor.coauthorSchmitt, Michael
dc.contributor.coauthorTerness, Peter
dc.contributor.coauthorSchmitt, Anita
dc.contributor.coauthorDaniel, Volker
dc.contributor.kuauthorSüsal, Caner
dc.contributor.kuprofileFaculty Member
dc.contributor.researchcenterKoç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM)
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid351800
dc.date.accessioned2024-11-09T23:58:44Z
dc.date.issued2023
dc.description.abstractBackground: We recently demonstrated that donor-derived modified immune cells (MICs)-PBMCs that acquire immunosuppressive properties after a brief treatment-induced specific immunosuppression against the allogeneic donor when administered before kidney transplantation. We found up to a 68-fold increase in CD19 + CD24 hi CD38 hi transitional B lymphocytes compared with transplanted controls. Methods: Ten patients from a phase 1 clinical trial who had received MIC infusions before kidney transplantation were followed to post-transplant day 1080. Results: Patients treated with MICs had a favorable clinical course, showing no donor-specific human leukocyte antigen antibodies or acute rejections. The four patients who had received the highest dose of MICs 7 days before surgery and were on reduced immunosuppressive therapy showed an absence of in vitro lymphocyte reactivity against stimulatory donor blood cells, whereas reactivity against third party cells was preserved. In these patients, numbers of transitional B lymphocytes were 75-fold and seven-fold higher than in 12 long-term survivors on minimal immunosuppression and four operationally tolerant patients, respectively ( P <0.001 for both). In addition, we found significantly higher numbers of other regulatory B lymphocyte subsets and a gene expression signature suggestive of operational tolerance in three of four patients. In MIC-treated patients, in vitro lymphocyte reactivity against donor blood cells was restored after B lymphocyte depletion, suggesting a direct pathophysiologic role of regulatory B lymphocytes in donor-specific unresponsiveness. Conclusions: These results indicate that donor-specific immunosuppression after MIC infusion is long-lasting and associated with a striking increase in regulatory B lymphocytes. Donor-derived MICs appear to be an immunoregulatory cell population that when administered to recipients before transplantation, may exert a beneficial effect on kidney transplants.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.indexedbyWoS
dc.description.issue1
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.volume34
dc.identifier.doi10.1681/ASN.2022020210
dc.identifier.issn1533-3450
dc.identifier.linkhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85142532651&doi=10.1681%2fASN.2022020210&partnerID=40&md5=94f6c0ab8376542d3a048a244b85ceaa
dc.identifier.scopus2-s2.0-85142532651
dc.identifier.urihttp://dx.doi.org/10.1681/ASN.2022020210
dc.identifier.urihttps://hdl.handle.net/20.500.14288/15519
dc.keywordsB-Lymphocytes, Regulatory
dc.keywordsHumans
dc.keywordsImmune tolerance
dc.keywordsImmunosuppression therapy
dc.keywordsImmunosuppressive agents
dc.keywordsKidney transplantation
dc.keywordsTransplant recipients
dc.keywordsImmunosuppressive agent
dc.keywordsGraft recipient
dc.keywordsHuman
dc.keywordsImmunological tolerance
dc.keywordsRegulatory B lymphocyte
dc.languageEnglish
dc.publisherWolters Kluwer Health
dc.sourceJournal of the American Society of Nephrology : JASN
dc.subjectCancer
dc.subjectB-Lymphocytes
dc.subjectInterleukin-10
dc.titleInduction of long-lasting regulatory B lymphocytes by modified immune cells in kidney transplant recipients
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0003-2521-8201
local.contributor.kuauthorSüsal, Caner

Files